- Report
- November 2026
- 292 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 495 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 224 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 208 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 757 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 561 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- May 2026
- 185 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- May 2026
- 185 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- May 2026
- 185 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- May 2026
- 185 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- May 2026
- 185 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- January 2026
- 181 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- January 2026
- 180 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- January 2026
- 180 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- November 2025
- 180 Pages
Global
From €4240EUR$4,500USD£3,530GBP
- Report
- July 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- April 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- March 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- March 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP
- Report
- February 2026
- 250 Pages
Global
From €4230EUR$4,490USD£3,522GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more